NCT04591639 - The DAPA-MEMRI Trial | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

July 28, 2028

Study Completion Date

July 28, 2028

Conditions

Heart FailureDiabetic Cardiomyopathies

Interventions

DRUG

Dapagliflozin 10 milligrams [Farxiga]

Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

DRUG

Placebo

Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.

Trial Locations (1)

RECRUITING

University of Edinburgh, Edinburgh